Back
Voyager Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
VYGR
Sponsored
DeFi Coin Triggers All "Buy" Signals And Could Break Out Soon
Discover our top DeFi pick for potentially massive gains now (before it's too late).
Sell
44
VYGR
Voyager Therapeutics
Last Price:
7.62
Seasonality Move:
1.94%
7 Day Trial
ALL ACCESS PASS
$
7
I love this overnight trade happening Thursday
Access my free presentation on these overnight trades right hereVoyager Therapeutics Price Quote
$7.62
Voyager Therapeutics Key Stats
Sell
44
Voyager Therapeutics (VYGR)
is a Sell
Day range:
$7.32 - $7.71
52-week range:
$6.06 - $14.34
Dividend yield:
0%
P/E ratio:
2.57
P/S ratio:
1.38
P/B ratio:
1.76%
Volume:
344.7K
Avg. volume:
747.4K
1-year change:
2.42%
Market cap:
$414.9M
Revenue:
$250M
EPS:
$3.03
How Much Does Voyager Therapeutics Make?
-
How Much Are Voyager Therapeutics's Sales Annually?
VYGR Revenues are $250M -
How Much Profit Does Voyager Therapeutics's Make A Year?
VYGR net income is $132.3M
Is Voyager Therapeutics Growing As A Company?
Data Unavailable
Voyager Therapeutics Stock Price Performance
-
Did Voyager Therapeutics Stock Go Up Last Month?
Voyager Therapeutics share price went down by -23.95% last month -
Did VYGR's Share Price Rise Over The Last Year?
VYGR share price rose by 2.42% over the past 1 year
What Is Voyager Therapeutics 52-Week High & Low?
-
What Is Voyager Therapeutics’s 52-Week High Share Price?
Voyager Therapeutics has traded as high as $14.34 over the past 52 weeks -
What Is Voyager Therapeutics’s 52-Week Low Share Price?
Voyager Therapeutics has traded as low as $6.06 over the past 52 weeks
Voyager Therapeutics Price To Free Cash Flow
-
Is Voyager Therapeutics Stock Overvalued?
Voyager Therapeutics is trading at a price to free cash flow ratio of 4.60 -
Is Voyager Therapeutics Stock Undervalued?
Voyager Therapeutics EV to Free Cash Flow ratio is 2.46 -
What Is Voyager Therapeutics’s Price Earnings Growth Ratio?
VYGR PEG ratio is 0.00 -
Is Voyager Therapeutics Trading At A Premium To Earnings?
Voyager Therapeutics EV to EBIT ratio is 1.51
Is It Risky To Buy Voyager Therapeutics?
-
How Much Debt Does Voyager Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Voyager Therapeutics Have?
Cash and short term investments quarterly total is $230.9M -
What Is Voyager Therapeutics’s Book Value Per Share?
Book value per share is 5.37
Is Voyager Therapeutics Cash Flow Positive?
-
What Is VYGR Cash Flow From Operations?
Cash flow from operations (TTM) is $77.9M -
What Is Voyager Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $33.6M -
What Is Voyager Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$141.6M
Voyager Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
VYGR return on invested capital is 74.55% -
What Is Voyager Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 45.41% -
What Is VYGR Return On Equity?
ROE is a measure of profitability and is 74.55%
Voyager Therapeutics Earnings Date & Stock Price
-
What Is Voyager Therapeutics's Stock Price Today?
A single share of VYGR can be purchased today for 7.62 -
What Is Voyager Therapeutics’s Stock Symbol?
Voyager Therapeutics trades on the nasdaq under the ticker symbol: VYGR -
When Is Voyager Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Voyager Therapeutics is scheduled on May 9, 2024 -
When Is VYGR's next ex-dividend date?
Voyager Therapeutics's next ex-dividend date is April 28, 2024 -
How To Buy Voyager Therapeutics Stock?
You can buy Voyager Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Voyager Therapeutics Competitors
-
Who Are Voyager Therapeutics's Competitors?
Below is a list of companies who compete with Voyager Therapeutics or are related in some way:
Voyager Therapeutics Dividend Yield
Data Unavailable
Voyager Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 881.25% |
Revenue: | 0% | 336.4% |
Analyst Recommendations
Buy Recommendations: | 8 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 17.78 |
Upside from Last Price: | 133.3% |